Isomorphic Labs announces a $5 billion Series C to move its first therapeutic programs toward clinical trials
Synopsis
Isomorphic Labs announced a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with new investors including a16z, continued significant investment from Alphabet, and participation from all existing investors. The company says the capital will fund further development of its proprietary drug-design engine IsoDDE, expansion of its internal and partnered drug-candidate portfolio, and construction of global infrastructure for AI-driven bioengineering and clinical translation. Isomorphic also says its internal oncology and immunology programs and partnered programs have produced positive preclinical results and are paving the way for its first therapeutic programs to enter clinical trials.
Interpretation
Isomorphic Labs announced a $5 billion Series C round, with the funds aimed at moving the company's first therapeutic programs into clinical trials. The company had been advancing through its proprietary drug-design engine and AI-designed candidate portfolio, building preclinical data in internal and partnered programs; this round raises the resource scale enough to expand models, pipeline and global bioengineering infrastructure at once. The round was co-led by Greenoaks and Sequoia Capital, with a16z and other new investors participating, continued significant investment from Alphabet, and participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK AI sovereign fund.
The money is earmarked for continued development of IsoDDE, combined with proprietary agents that navigate and reason over complex biological systems, for molecular design across therapeutic areas and drug modalities. IsoDDE unifies a suite of simulation foundation models that work natively across multiple therapeutic areas and drug modalities, rather than building separately for a single modality. The company says IsoDDE's simulation models approach experimental-level prediction accuracy in breadth and precision, and that combined with the agents they repeatedly translate into progress across its multimodal therapeutic candidate portfolio.
The company cites positive preclinical results as the basis for moving toward the clinical stage, covering internal oncology and immunology programs as well as partnered programs. The announcement describes current progress as these programs having positive preclinical results and paving the way for entry into the clinical stage. This statement comes from the company's own funding announcement, which gives no specific molecules, number of indications or preclinical data values.
Perspective
The report is limited to Isomorphic Labs' Series C announcement itself: the amount, lead and participating investors, use of funds, and the company's description of IsoDDE and pipeline progress. The announcement addresses investors and the public and describes company-level plans and self-reported progress; it does not establish efficacy or clinical outcomes for any candidate drug.
The announcement says internal oncology and immunology programs and partnered programs have positive preclinical results, but gives no molecules, indications, sample sizes or specific metrics. It says IsoDDE's simulation models approach experimental-level prediction accuracy, again without comparison experiments or error values. Entry into the clinical stage is described as being paved, not as already started.
